Processing

Please wait...

Settings

Settings

1. WO2020006125 - METHODS OF TREATING MITOCHONDRIAL DYSFUNCTION

Publication Number WO/2020/006125
Publication Date 02.01.2020
International Application No. PCT/US2019/039317
International Filing Date 26.06.2019
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
12
Ketones
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
337
having four-membered rings, e.g. taxol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
35
having six-membered rings with one oxygen as the only ring hetero atom
352
condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/12 (2006.01)
A61K 31/337 (2006.01)
A61K 31/352 (2006.01)
CPC
A61K 31/10
A61K 31/12
A61K 31/337
A61K 31/352
A61K 45/06
A61K 9/00
Applicants
  • RIBONOVA INC. [US/US]; Lankenau Institute for Medical Research R133 100 East Lancaster Avenue Wynnewood, Pennsylvania 19096, US
Inventors
  • FALK, Marni J.; US
  • MCCORMACK, Shana E.; US
  • ZOLKIPLI-CUNNINGHAM, Zarazuela; US
  • WEBB, Nigel L.; US
  • YUEN, Eric C.; US
  • FORD-HUTCHINSON, Anthony W.; US
Agents
  • SMYTH, Robert J.; US
  • BEARDELL, Louis W.; US
Priority Data
62/689,99626.06.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF TREATING MITOCHONDRIAL DYSFUNCTION
(FR) MÉTHODES DE TRAITEMENT D'UN DYSFONCTIONNEMENT MITOCHONDRIAL
Abstract
(EN)
This disclosure is directed to methods of treating or preventing mitochondrial dysfunction or mitochondrial disease in a subject comprising administration of probucol, or a pharmaceutically acceptable salt thereof. This disclosure is also directed to methods of diagnosing genetic mitochondrial disease in a subject prior to and in association with said treatment or prevention. This disclosure is also directed to methods of assessing and managing a subject with mitochondrial dysfunction or mitochondrial disease using a composite measurement.
(FR)
La présente invention concerne des méthodes de traitement ou de prévention d'un dysfonctionnement mitochondrial ou d'une maladie mitochondriale chez un sujet comprenant l'administration de probucol, ou d'un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne également des méthodes de diagnostic d'une maladie mitochondriale génétique chez un sujet avant et en association avec ledit traitement ou ladite prévention. La présente invention concerne également des méthodes d'évaluation et de prise en charge d'un sujet atteint d'un dysfonctionnement mitochondrial ou d'une maladie mitochondriale à l'aide d'une mesure composite.
Latest bibliographic data on file with the International Bureau